Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S. Gogola E, et al. Among authors: borst p. Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Cancer Cell. 2018. PMID: 29894693 Free article.
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.
Duarte AA, Gogola E, Sachs N, Barazas M, Annunziato S, R de Ruiter J, Velds A, Blatter S, Houthuijzen JM, van de Ven M, Clevers H, Borst P, Jonkers J, Rottenberg S. Duarte AA, et al. Among authors: borst p. Nat Methods. 2018 Feb;15(2):134-140. doi: 10.1038/nmeth.4535. Epub 2017 Dec 11. Nat Methods. 2018. PMID: 29256493
What makes tumors multidrug resistant?
Borst P, Jonkers J, Rottenberg S. Borst P, et al. Cell Cycle. 2007 Nov 15;6(22):2782-7. doi: 10.4161/cc.6.22.4936. Epub 2007 Aug 23. Cell Cycle. 2007. PMID: 17998803 Review.
How do real tumors become resistant to cisplatin?
Borst P, Rottenberg S, Jonkers J. Borst P, et al. Cell Cycle. 2008 May 15;7(10):1353-9. doi: 10.4161/cc.7.10.5930. Epub 2008 Mar 17. Cell Cycle. 2008. PMID: 18418074 Review.
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. Rottenberg S, et al. Among authors: borst p. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29. Proc Natl Acad Sci U S A. 2008. PMID: 18971340 Free PMC article.
Drug resistance in the mouse cancer clinic.
Rottenberg S, Borst P. Rottenberg S, et al. Among authors: borst p. Drug Resist Updat. 2012 Feb-Apr;15(1-2):81-9. doi: 10.1016/j.drup.2012.01.001. Epub 2012 Feb 14. Drug Resist Updat. 2012. PMID: 22335919 Free article. Review.
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. Rottenberg S, et al. Among authors: borst p. Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6. Cancer Res. 2012. PMID: 22396490 Free PMC article.
474 results